Mindblown: a blog about philosophy.
Australia stocks higher at close of trade; S&P/ASX 200 up 1.42%
Investing.com – Australia stocks were higher after the close on Wednesday, as gains in the A-REITs, Gold and IT sectors led shares higher. At the close in Sydney, the S&P/ASX 200 gained 1.42% to hit a new 1-month high. The best performers of the session on the S&P/ASX 200 were Charter Hall Group (ASX:CHC), which […]
Australia stocks higher at close of trade; S&P/ASX 200 up 1.42%
Investing.com – Australia stocks were higher after the close on Wednesday, as gains in the A-REITs, Gold and IT sectors led shares higher. At the close in Sydney, the S&P/ASX 200 gained 1.42% to hit a new 1-month high. The best performers of the session on the S&P/ASX 200 were Charter Hall Group (ASX:CHC), which […]
Australia stocks higher at close of trade; S&P/ASX 200 up 1.42%
Investing.com – Australia stocks were higher after the close on Wednesday, as gains in the A-REITs, Gold and IT sectors led shares higher. At the close in Sydney, the S&P/ASX 200 gained 1.42% to hit a new 1-month high. The best performers of the session on the S&P/ASX 200 were Charter Hall Group (ASX:CHC), which […]
Australia stocks higher at close of trade; S&P/ASX 200 up 1.42%
Investing.com – Australia stocks were higher after the close on Wednesday, as gains in the A-REITs, Gold and IT sectors led shares higher. At the close in Sydney, the S&P/ASX 200 gained 1.42% to hit a new 1-month high. The best performers of the session on the S&P/ASX 200 were Charter Hall Group (ASX:CHC), which […]
Australia stocks higher at close of trade; S&P/ASX 200 up 1.42%
Investing.com – Australia stocks were higher after the close on Wednesday, as gains in the A-REITs, Gold and IT sectors led shares higher. At the close in Sydney, the S&P/ASX 200 gained 1.42% to hit a new 1-month high. The best performers of the session on the S&P/ASX 200 were Charter Hall Group (ASX:CHC), which […]
IGM Biosciences reports increased Q3 net loss, progress in trials
IGM Biosciences (NASDAQ:IGMS) Inc, a biotechnology company focusing on the development of immunoglobulin M (IgM) antibodies for the treatment of cancer and other diseases, reported a net loss of $61.9 million for the third quarter of 2023. This represents an increase from the net loss of $58.0 million reported in the same period last year. […]
IGM Biosciences reports increased Q3 net loss, progress in trials
IGM Biosciences (NASDAQ:IGMS) Inc, a biotechnology company focusing on the development of immunoglobulin M (IgM) antibodies for the treatment of cancer and other diseases, reported a net loss of $61.9 million for the third quarter of 2023. This represents an increase from the net loss of $58.0 million reported in the same period last year. […]
IGM Biosciences reports increased Q3 net loss, progress in trials
IGM Biosciences (NASDAQ:IGMS) Inc, a biotechnology company focusing on the development of immunoglobulin M (IgM) antibodies for the treatment of cancer and other diseases, reported a net loss of $61.9 million for the third quarter of 2023. This represents an increase from the net loss of $58.0 million reported in the same period last year. […]
IGM Biosciences reports increased Q3 net loss, progress in trials
IGM Biosciences (NASDAQ:IGMS) Inc, a biotechnology company focusing on the development of immunoglobulin M (IgM) antibodies for the treatment of cancer and other diseases, reported a net loss of $61.9 million for the third quarter of 2023. This represents an increase from the net loss of $58.0 million reported in the same period last year. […]
IGM Biosciences reports increased Q3 net loss, progress in trials
IGM Biosciences (NASDAQ:IGMS) Inc, a biotechnology company focusing on the development of immunoglobulin M (IgM) antibodies for the treatment of cancer and other diseases, reported a net loss of $61.9 million for the third quarter of 2023. This represents an increase from the net loss of $58.0 million reported in the same period last year. […]
Got any book recommendations?